PNET
MCID: PNC119
MIFTS: 47

Pancreatic Neuroendocrine Tumor (PNET)

Categories: Cancer diseases, Endocrine diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Pancreatic Neuroendocrine Tumor

MalaCards integrated aliases for Pancreatic Neuroendocrine Tumor:

Name: Pancreatic Neuroendocrine Tumor 53 37
Neuroendocrine Tumor of Pancreas 53 6
Islet Cell Tumor 53 73
Well-Differentiated Neuroendocrine Neoplasm of Pancreas 53
Well-Differentiated Pancreatic Neuroendocrine Neoplasm 53
Well Differentiated Pancreatic Endocrine Tumor 73
Well-Differentiated Nen of Pancreas 53
Pancreatic Neuroendocrine Neoplasm 53
Well-Differentiated Pancreatic Nen 53
Pancreatic Endocrine Tumor 53
Pancreatic Net 53
Pnet 53

Classifications:



External Ids:

KEGG 37 H00045

Summaries for Pancreatic Neuroendocrine Tumor

NIH Rare Diseases : 53 A pancreatic neuroendocrine tumor, also called an islet cell tumor, is a type of neuroendocrine tumor (NET) that typically arises in the pancreas. However in some cases, a pancreatic NET occurs outside of the pancreas. A NET arises from cells that produce hormones, so the tumor can also produce hormones. It may be benign (not cancerous) or malignant (cancerous). Pancreatic NETs usually grow slowly over many years, but there are fast-growing forms. Pancreatic NETs are called either functional or nonfunctional. A functional pancreatic NET causes specific symptoms because it makes extra hormones, such as gastrin, insulin, or glucagon. Examples of types of functional pancreatic NETs include insulinomas, glucagonomas, gastrinomas, VIPomas, and somatostatinomas. Symptoms depend on the type of hormone being made. A nonfunctional pancreatic NET generally does not cause specific symptoms, but may eventually cause symptoms relating to its location and size as it grows or spreads. Pancreatic NETs can be hard to diagnosis, often not identified until 5 to 10 years after they begin to grow. Most pancreatic NETs are not inherited and occur sporadically in people with no family history of NETs. However, about 10% are associated with a hereditary cancer or tumor syndrome such as multiple endocrine neoplasia type 1 (MEN1), which has autosomal dominant inheritance. Treatment options for each person depend on many factors including the type of tumor, its location, whether it has spread to other parts of the body (metastasized), and symptoms present. Treatment options may include surgery to remove all or part of the tumor (and sometimes the lymph nodes), and/or nonsurgical treatments to shrink the tumor, stop it from growing, or alleviate symptoms. The chance of recovery (prognosis) also depends upon these factors and differs from person to person.

MalaCards based summary : Pancreatic Neuroendocrine Tumor, also known as neuroendocrine tumor of pancreas, is related to glioma and pancreas adenocarcinoma. An important gene associated with Pancreatic Neuroendocrine Tumor is BRCA2 (BRCA2, DNA Repair Associated), and among its related pathways/superpathways are Human Thyroid Stimulating Hormone (TSH) signaling pathway and IL2 signaling events mediated by PI3K. The drugs Afinitor and Sutent have been mentioned in the context of this disorder. Affiliated tissues include pancreas, liver and lymph node, and related phenotypes are behavior/neurological and nervous system

Wikipedia : 76 Pancreatic neuroendocrine tumors (PanNETs, PETs, or PNETs), often referred to as "islet cell tumors", or... more...

Related Diseases for Pancreatic Neuroendocrine Tumor

Diseases related to Pancreatic Neuroendocrine Tumor via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 185)
# Related Disease Score Top Affiliating Genes
1 glioma 29.6 BRCA2 MEG3 PIK3CA
2 pancreas adenocarcinoma 29.6 BRCA2 PALB2 PIK3CA
3 glioblastoma 29.2 BRCA2 MEG3 MTOR PIK3CA
4 pancreatic cancer 28.9 BRCA2 MEG3 MTOR PALB2 PIK3CA
5 breast cancer 28.7 BRCA2 MEG3 MKI67 MTOR PALB2 PIK3CA
6 islet cell tumor 12.6
7 pheochromocytoma--islet cell tumor syndrome 12.5
8 non-functioning pancreatic endocrine tumor 12.4
9 functioning pancreatic endocrine tumor 12.3
10 ewing sarcoma 12.0
11 neuroendocrine tumor 11.8
12 insulinoma 11.7
13 von hippel-lindau syndrome 11.6
14 pineoblastoma 11.6
15 non-functioning neuroendocrine tumor of pancreas 11.6
16 somatostatinoma 11.5
17 supratentorial primitive neuroectodermal tumor 11.5
18 medulloblastoma 11.4
19 mahvash disease 11.4
20 insulinomatosis and diabetes mellitus 11.3
21 vipoma 11.3
22 neuroendocrine carcinoma of pancreas 11.2
23 serotonin-producing neuroendocrine tumor of pancreas 11.2
24 pancreatic endocrine carcinoma 11.2
25 ependymoblastoma 11.0
26 pineoblastoma, childhood 11.0
27 adult central nervous system primitive neuroectodermal neoplasm 11.0
28 childhood central nervous system primitive neuroectodermal neoplasm 11.0
29 cerebellopontine angle primitive neuroectodermal 11.0
30 intracranial primitive neuroectodermal tumor 11.0
31 spinal cord primitive neuroectodermal neoplasm 11.0
32 cerebral primitive neuroectodermal tumor 11.0
33 ewing's family of tumors 10.7
34 multiple endocrine neoplasia 10.5
35 multiple endocrine neoplasia, type i 10.5
36 hyperinsulinism 10.4
37 adenocarcinoma 10.4
38 zollinger-ellison syndrome 10.3
39 renal cell carcinoma, nonpapillary 10.2
40 hemangiopericytoma, malignant 10.1
41 pancreatitis 10.1
42 hypoglycemia 10.1
43 dermatosis papulosa nigra 10.1 MTOR PIK3CA
44 squamous cell carcinoma of the oral tongue 10.1 MKI67 PIK3CA
45 meningioma, radiation-induced 10.1 MEG3 MKI67
46 ovarian epithelial cancer 10.1 MEG3 PIK3CA
47 hemimegalencephaly 10.1 MTOR PIK3CA
48 megalencephaly 10.1 MTOR PIK3CA
49 ovarian clear cell adenocarcinoma 10.1 MTOR PIK3CA
50 teratoma 10.1

Graphical network of the top 20 diseases related to Pancreatic Neuroendocrine Tumor:



Diseases related to Pancreatic Neuroendocrine Tumor

Symptoms & Phenotypes for Pancreatic Neuroendocrine Tumor

MGI Mouse Phenotypes related to Pancreatic Neuroendocrine Tumor:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.43 BRCA2 CACNA1A CLU MTOR PALB2 PIK3CA
2 nervous system MP:0003631 9.1 BRCA2 CACNA1A CLU MTOR PALB2 PIK3CA

Drugs & Therapeutics for Pancreatic Neuroendocrine Tumor

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Afinitor 18 49 EVEROLIMUS Novartis March 2009
2
Sutent 18 49 SUNITINIB MALATE Pfizer May 2011/ January 2006

Drugs for Pancreatic Neuroendocrine Tumor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 166)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sunitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 557795-19-4, 341031-54-7 5329102
2
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1 159351-69-6 6442177
3
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53123-88-9 46835353 6436030 5284616
4
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
5
Levoleucovorin Approved, Investigational Phase 4,Phase 2,Phase 3 68538-85-2
6
Oxaliplatin Approved, Investigational Phase 4,Phase 2,Phase 3 61825-94-3 43805 6857599 5310940 9887054
7
leucovorin Approved Phase 4,Phase 2,Phase 3 58-05-9 6006 143
8
Fluorouracil Approved Phase 4,Phase 2,Phase 3 51-21-8 3385
9
Somatostatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 51110-01-1, 38916-34-6 53481605
10
Pancrelipase Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 53608-75-6
11
Streptozocin Approved, Investigational Phase 4,Phase 3,Phase 2 18883-66-4 29327
12
Capecitabine Approved, Investigational Phase 4,Phase 2,Phase 1 154361-50-9 60953
13
Dacarbazine Approved, Investigational Phase 4,Phase 2,Phase 1 4342-03-4 5351166
14
Temozolomide Approved, Investigational Phase 4,Phase 2,Phase 1 85622-93-1 5394
15
Pasireotide Approved Phase 4,Phase 2,Phase 1 396091-73-9 9941444
16
Gemcitabine Approved Phase 4 95058-81-4 60750
17
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 59-30-3 6037
18 Angiogenesis Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
19 Angiogenesis Modulating Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
20 Immunologic Factors Phase 4,Phase 2,Phase 3,Phase 1
21 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
22 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1
23 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
24 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
25 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1
26 Antiviral Agents Phase 4,Phase 2,Phase 1
27 Vitamin B9 Phase 4,Phase 2,Phase 3,Phase 1
28 Antimetabolites Phase 4,Phase 2,Phase 3,Phase 1
29 Folate Phase 4,Phase 2,Phase 3,Phase 1
30 Antimetabolites, Antineoplastic Phase 4,Phase 2,Phase 3,Phase 1
31 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
32 Hormones Phase 4,Phase 3,Phase 2,Phase 1
33 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
34 Hypoglycemic Agents Phase 4,Phase 2,Phase 1
35 pancreatin Phase 4,Phase 2,Phase 1,Not Applicable
36 Micronutrients Phase 4,Phase 2,Phase 1
37 Antidotes Phase 4,Phase 2
38 Vitamins Phase 4,Phase 2,Phase 1
39 Antineoplastic Agents, Alkylating Phase 4,Phase 2,Phase 1
40 Protective Agents Phase 4,Phase 2
41 Vitamin B Complex Phase 4,Phase 2,Phase 1
42 Alkylating Agents Phase 4,Phase 2,Phase 1
43 Trace Elements Phase 4,Phase 2,Phase 1
44 Insulin, Globin Zinc Phase 4,Not Applicable
45 insulin Phase 4,Not Applicable
46 Fluorodeoxyglucose F18 Phase 4,Phase 2
47 Hematinics Phase 4
48
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
49 lanreotide Approved Phase 3,Phase 2 108736-35-2
50
Dopamine Approved Phase 3 51-61-6, 62-31-7 681

Interventional clinical trials:

(show top 50) (show all 147)
# Name Status NCT ID Phase Drugs
1 Clinical Effectiveness of Serum Chromogranin A Levels on Diagnostic of Pancreatic Neuroendocrine Tumors Unknown status NCT02759718 Phase 4
2 A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors Completed NCT01525550 Phase 4 sunitinib
3 Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China Recruiting NCT02842749 Phase 4 everolimus
4 Nonfunctional Pancreatic NET and PET Imaging Recruiting NCT02621541 Phase 4
5 MGMT-NET: O6-methylguanine-DNA Methyltransferase (MGMT) Status in Neuroendocrine Tumors: Predictive Factor of Response to Alkylating Agents Recruiting NCT03217097 Phase 4 Oxaliplatin-based chemotherapy;Alkylating-based chemotherapy
6 Pasireotide Treatment for Neuroendocrine Tumor Withdrawn NCT02779257 Phase 4 Pasireotide;Diazoxide
7 Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors Unknown status NCT00227617 Phase 2, Phase 3 5-fluorouracil;leucovorin;oxaliplatin
8 Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero- Pancreatic Endocrine Tumour Completed NCT00842348 Phase 3 lanreotide (Autogel formulation)
9 Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours Completed NCT00353496 Phase 3 lanreotide (Autogel formulation);Placebo
10 Efficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine Tumors Completed NCT00510068 Phase 3 Everolimus;Everolimus Placebo
11 A Study Evaluating Lanreotide as Maintenance Therapy in Patients With Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors (REMINET) Recruiting NCT02288377 Phase 2, Phase 3 lanreotide;Placebo
12 Phase III Study of Surufatinib in Treating Advanced Pancreatic Neuroendocrine Tumors Recruiting NCT02589821 Phase 3 Surufatinib
13 Efficacy and Safety of Everolimus and (STZ-5FU) Given One Upfront the Other Upon Progression in Advanced pNET Recruiting NCT02246127 Phase 3 Drug: Everolimus;STZ-5FU
14 18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety Recruiting NCT03042416 Phase 3 18F-DOPA
15 Cabozantinib S-malate in Treating Patients With Neuroendocrine Tumors Previously Treated With Everolimus That Are Locally Advanced, Metastatic, or Cannot Be Removed by Surgery Recruiting NCT03375320 Phase 3 Cabozantinib S-malate
16 Non-functioning Pancreatic Neuroendocrine Tumors in MEN1: Somatostatin Analogs Versus NO Treatment Not yet recruiting NCT02705651 Phase 3 Somatostatin-Analog
17 A Study Of Sunitinib Compared To Placebo For Patients With Advanced Pancreatic Islet Cell Tumors Terminated NCT00428597 Phase 3 sunitinib malate;Placebo
18 Activity and Safety of Everolimus+Octreotide LAR+Metformin in Advanced Pancreatic Well-differentiated NETs Unknown status NCT02294006 Phase 2 Everolimus plus Octreotide LAR plus Metformin
19 Docetaxel With or Without Low-dose, Short Course Sunitinib in Refractory Solid Tumors Unknown status NCT01803503 Phase 2 Docetaxel;Sunitinib
20 Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer Unknown status NCT02188550 Phase 2 everolimus and letrozole
21 Recombinant Anti-tumor and Anti-virus Protein for Injection to Treat Advanced Neuroendocrine Tumors Unknown status NCT02455596 Phase 2 Recombinant anti-tumor and anti-virus protein for injection (Novaferon)
22 BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy. Completed NCT01658436 Phase 2 BEZ235 (Stage 1)
23 Chemotherapy Plus Endostatin in Advanced Pancreatic Neuroendocrine Tumor Completed NCT01845675 Phase 2 temozolomide or dacarbazine-based chemotherapy, endostatin
24 A Biological Prospective Study in Patients With Metastatic Pancreatic NETs Treated With Everolimus Completed NCT02305810 Phase 2 Everolimus 10 mg daily
25 Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors Completed NCT01121562 Phase 2 Sunitinib
26 68-Ga-labeled Octreotide Analogues PET in Duodenal-pancreatic Neuroendocrine Tumours Completed NCT01673906 Phase 2 Diagnostic work up
27 AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors Completed NCT01024387 Phase 2 AMG 479
28 A Trial to Assess the Activity and Safety of Palbociclib in Patients With Well and Moderately Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET) Completed NCT02806648 Phase 2 Palbociclib
29 Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery Completed NCT02101918 Phase 2
30 Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET Completed NCT02231762 Phase 2 Lanreotide Autogel 120 mg;Temozolomide (TMZ)
31 Combination Chemotherapy in Patients With Zollinger-Ellison Syndrome and Tumors of the Pancreas Completed NCT00001165 Phase 2 combined chemotherapy with streptozotocin, 5-fluorouracil, and doxorubicin
32 Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy Completed NCT00363051 Phase 2 Everolimus 10 mg;Octreotide Depot
33 Interferon and Octreotide to Treat Zollinger-Ellison Syndrome and Advanced Non-B Islet Cell Cancer Completed NCT00001228 Phase 2 Interferon
34 Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery Completed NCT00416767 Phase 2 fluorouracil;irinotecan hydrochloride;leucovorin calcium
35 68Ga-OPS202 Study for Diagnostic Imaging of GEP NET Completed NCT02162446 Phase 1, Phase 2 satoreotide trizoxetan
36 Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors Completed NCT00602082 Phase 2 capecitabine;cisplatin;streptozocin
37 KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors Completed NCT02250885 Phase 2 Selinexor
38 Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization Completed NCT00434109 Phase 2 Sunitinib malate
39 PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors Completed NCT00017199 Phase 2 bortezomib
40 A Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated Biomarkers Completed NCT02132468 Phase 2 fosbretabulin tromethamine
41 Sunitinib in Never-Smokers With Lung Adenocarcinoma Completed NCT01829217 Phase 2 Sunitinib
42 AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors Completed NCT00427349 Phase 2 AMG 706;octreotide
43 Pazopanib as Single Agent in Advanced NETs Completed NCT01280201 Phase 2 Pazopanib
44 The Use of Oral Omeprazole and Intravenous Pantoprazole in Patients With Hypersecretion of Gastric Acid Completed NCT00001191 Phase 2 Pantoprazole;Omeprazole
45 Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET) Completed NCT00610129 Phase 2 MK-0646
46 Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors Completed NCT00027638 Phase 2 thalidomide
47 Isolated Hepatic Perfusion With Melphalan in Treating Patients With Primary Unresectable Liver Cancer or Liver Metastases Completed NCT00019786 Phase 2 isolated perfusion;melphalan
48 68Ga-DOTATATE PET Scan in Neuroendocrine Cancer Completed NCT01396382 Phase 2
49 A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Pancreatic Neuroendocrine Tumor Recruiting NCT03204019 Phase 2 Tegafur and Temozolomide;Tegafur and Temozolomide combined with Thalidomide
50 177Lutethium - Peptide Receptor Radionuclide Therapy (Lu-PRRT) Plus Capecitabine Versus Lu-PRRT in FDG Positive, Gastro-entero-pancreatic Neuroendocrine Tumors Recruiting NCT02736448 Phase 2 Capecitabine;Lu-PRRT;SS-LAR

Search NIH Clinical Center for Pancreatic Neuroendocrine Tumor

Genetic Tests for Pancreatic Neuroendocrine Tumor

Anatomical Context for Pancreatic Neuroendocrine Tumor

MalaCards organs/tissues related to Pancreatic Neuroendocrine Tumor:

41
Pancreas, Liver, Lymph Node, Spleen, Lung, Ovary, Thyroid

Publications for Pancreatic Neuroendocrine Tumor

Articles related to Pancreatic Neuroendocrine Tumor:

(show top 50) (show all 283)
# Title Authors Year
1
Role of palliative resection of the primary pancreatic neuroendocrine tumor in patients with unresectable metastatic liver disease: a systematic review and meta-analysis. ( 29503572 )
2018
2
Reply to: Genotype-Phenotype Pancreatic Neuroendocrine Tumor Relationship in Multiple Endocrine Neoplasia Type 1 Patients: A 23 Year Experience at a Single Institution. ( 29859614 )
2018
3
Establishment of the First Well-differentiated Human Pancreatic Neuroendocrine Tumor Model. ( 29330294 )
2018
4
Hepatobiliary and Pancreatic: Malignant pancreatic perivascular epithelioid cell tumor mimicking pancreatic neuroendocrine tumor. ( 29888489 )
2018
5
Pancreatic neuroendocrine tumor: review of heterogeneous spectrum of CT appearance. ( 29594467 )
2018
6
Genotype-phenotype pancreatic neuroendocrine tumor relationship in multiple endocrine neoplasia type 1 patients: A 23-year experience at a single institution. ( 29122330 )
2018
7
Prognostic factors of non-functioning pancreatic neuroendocrine tumor revisited: The value of WHO 2010 classification. ( 29536058 )
2018
8
Hypoglycemia in a Patient With a Polyhormonal Pancreatic Neuroendocrine Tumor With Evidence of Endocrine Progenitors. ( 29568813 )
2018
9
Intrapancreatic Accessory Spleen Masquerading as a Pancreatic Neuroendocrine Tumor. ( 29404984 )
2018
10
Agenesis of dorsal pancreas associated with pancreatic neuroendocrine tumor: a case report and review of the literature. ( 29958547 )
2018
11
Demonstration of 68Ga-prostate-specific Membrane Antigen Uptake in Metastatic Pancreatic Neuroendocrine Tumor. ( 29962731 )
2018
12
Prognostic factors and survival after surgical resection of pancreatic neuroendocrine tumor with validation of established and modified staging systems. ( 29576279 )
2018
13
Cystic pancreatic neuroendocrine tumor. Pancreatic endocrine or neuroendocrine tumor. Endoscopic ultrasonography. ( 29313698 )
2018
14
Letter to the editors regarding: genotype-phenotype pancreatic neuroendocrine tumor relationship in multiple endocrine neoplasia type 1 patients: a 23-year experience at a single institution. ( 29338880 )
2018
15
A case of pancreatic neuroendocrine tumor with multiple cystic components of various sizes. ( 29270782 )
2018
16
Contrast harmonic EUS for the prediction of pancreatic neuroendocrine tumor aggressiveness (with videos). ( 29325706 )
2018
17
Site-Specific Genomic Alterations in a Well-Differentiated Pancreatic Neuroendocrine Tumor With High-Grade Progression. ( 29521944 )
2018
18
Two-stage resection of a bilateral pheochromocytoma and pancreatic neuroendocrine tumor in a patient with von Hippel-Lindau disease: A case report. ( 29501019 )
2018
19
Fine-needle aspiration of a pancreatic neuroendocrine tumor with prominent rhabdoid features. ( 29359517 )
2018
20
Gastric metastasis from pancreatic neuroendocrine tumor. ( 29634914 )
2018
21
Prediction of Pancreatic Neuroendocrine Tumor Grade Based on CT Features and Texture Analysis. ( 29140113 )
2018
22
Differentiation between pancreatic metastases from clear cell renal cell carcinoma and pancreatic neuroendocrine tumor using double-echo chemical shift imaging. ( 29500651 )
2018
23
Decreased expression of LKB1 predicts poor prognosis in pancreatic neuroendocrine tumor patients undergoing curative resection. ( 29563804 )
2018
24
Role of surgery in pancreatic neuroendocrine tumor. ( 29629318 )
2018
25
Novel recurrence risk stratification of resected pancreatic neuroendocrine tumor. ( 29107104 )
2018
26
Incidental Detection of Asymptomatic Brain Metastases on<sup>18</sup>F-fluoride Positron Emission Tomography/Computed Tomography and<sup>68</sup>Ga DOTANOC Positron Emission Tomography/Computed Tomography in a Patient with Concomitant Breast Carcinoma and a Pancreatic Neuroendocrine Tumor. ( 29398971 )
2018
27
Development of a class prediction model to discriminate pancreatic ductal adenocarcinoma from pancreatic neuroendocrine tumor by MALDI mass spectrometry imaging. ( 30548962 )
2018
28
Correction to: Pre-therapy Somatostatin Receptor-Based Heterogeneity Predicts Overall Survival in Pancreatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide Therapy. ( 30109540 )
2018
29
Simple Vascular Architecture Classification in Predicting Pancreatic Neuroendocrine Tumor Grade and Prognosis. ( 30121810 )
2018
30
Large cardiac metastasis from pancreatic neuroendocrine tumor and response to peptide receptor radionuclide therapy with 177Lu-DOTATATE. ( 30151794 )
2018
31
Incidental finding of a breast carcinoma on Ga-68-DOTA-1-Nal3-octreotide positron emission tomography/computed tomography performed for the evaluation of a pancreatic neuroendocrine tumor: A case report. ( 30200073 )
2018
32
Margin status and long-term prognosis of primary pancreatic neuroendocrine tumor after curative resection: Results from the US Neuroendocrine Tumor Study Group. ( 30278986 )
2018
33
Diagnosing microscopic pancreatic neuroendocrine tumor using 68-Ga-DOTATATE PET/CT: case series. ( 30283629 )
2018
34
Percutaneous Transhepatic Approach for Recanalization of Superior Mesenteric and Portal Vein in a Patient With Pancreatic Neuroendocrine Tumor Presenting With Bleeding Duodenal Varices: A Brief Case Report. ( 30302050 )
2018
35
Pharmacological Inhibition of Class IIA HDACs by LMK-235 in Pancreatic Neuroendocrine Tumor Cells. ( 30321986 )
2018
36
Diffuse Pancreatic Neuroendocrine Tumor: A Rare Presentation. ( 30386066 )
2018
37
Cell-Free DNA From Metastatic Pancreatic Neuroendocrine Tumor Patients Contains Tumor-Specific Mutations and Copy Number Variations. ( 30443491 )
2018
38
Sporadic pancreatic neuroendocrine tumor: Surgery of the primary tumor. ( 30448206 )
2018
39
ASO Author Reflections: Pancreatic Neuroendocrine Tumor Recurrence and Survival Predicted by Ki67. ( 30519760 )
2018
40
Ectopic corticotropin-releasing hormone syndrome caused by pancreatic neuroendocrine tumor localized by 68Ga-DOTATATE PET/CT. ( 30519868 )
2018
41
Late metachronous isolated pancreatic metastasis from renal cell carcinoma mimicking a pancreatic neuroendocrine tumor. ( 30541739 )
2018
42
Occipital Headache as Initial Manifestation of a Pancreatic Neuroendocrine Tumor. ( 28283989 )
2018
43
Pancreatic neuroendocrine tumor: Correlations between MRI features, tumor biology, and clinical outcome after surgery. ( 28480609 )
2018
44
Two Childhood Pheochromocytoma Cases due to von Hippel-Lindau Disease, One Associated with Pancreatic Neuroendocrine Tumor: A Very Rare Manifestation ( 29022557 )
2018
45
Association of VHL Genotype With Pancreatic Neuroendocrine Tumor Phenotype in Patients With von Hippel-Lindau Disease. ( 29075773 )
2018
46
Pre-therapy Somatostatin Receptor-Based Heterogeneity Predicts Overall Survival in Pancreatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide Therapy. ( 30014345 )
2018
47
Epidrug-induced upregulation of functional somatostatin type 2 receptors in human pancreatic neuroendocrine tumor cells. ( 29599907 )
2018
48
Insulin Expressing Pancreatic Neuroendocrine Tumor Associated With Intratumor Amyloidosis. ( 28648398 )
2017
49
An Elderly Man With Pancreatic Neuroendocrine Tumor and a Cavitary Right Upper Lobe Lung Mass. ( 28599947 )
2017
50
MEG3 Suppresses Human Pancreatic Neuroendocrine Tumor Cells Growth and Metastasis by Down-Regulation of Mir-183. ( 29132136 )
2017

Variations for Pancreatic Neuroendocrine Tumor

ClinVar genetic disease variations for Pancreatic Neuroendocrine Tumor:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 BRCA2 NM_000059.3(BRCA2): c.994dupA (p.Ile332Asnfs) duplication Pathogenic rs397508066 GRCh37 Chromosome 13, 32906609: 32906609
2 BRCA2 NM_000059.3(BRCA2): c.994dupA (p.Ile332Asnfs) duplication Pathogenic rs397508066 GRCh38 Chromosome 13, 32332472: 32332472
3 PALB2 NM_024675.3(PALB2): c.778C> T (p.Gln260Ter) single nucleotide variant Pathogenic GRCh37 Chromosome 16, 23647089: 23647089
4 PALB2 NM_024675.3(PALB2): c.778C> T (p.Gln260Ter) single nucleotide variant Pathogenic GRCh38 Chromosome 16, 23635768: 23635768

Copy number variations for Pancreatic Neuroendocrine Tumor from CNVD:

7 (show all 16)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 36717 1 79269825 120225489 Loss DDA3 Pancreatic endocrine tumor
2 38231 10 1 77700000 Gain RET Pancreatic endocrine tumor
3 40010 10 123100000 127500000 Loss DMBT1 Pancreatic endocrine tumor
4 45931 10 75266020 135228726 Loss PTEN Pancreatic endocrine tumor
5 49582 11 108093559 108239826 Loss ATM Pancreatic endocrine tumor
6 49994 11 112500000 114500000 Loss PPP2R1B Pancreatic endocrine tumor
7 117037 17 70900000 81195210 Loss FAS Pancreatic endocrine tumor
8 151222 20 18623480 62342703 Gain BCAS1 Pancreatic endocrine tumor
9 162982 22 23484416 48053047 Loss CHEK2 Pancreatic endocrine tumor
10 166156 3 1 91700000 Indels Pancreatic endocrine tumor
11 176562 3 49525778 51884070 Loss IFRD2 Pancreatic endocrine tumor
12 179191 3 8700000 16400000 Loss FANCD2 Endocrine pancreatic tumor
13 191665 5 1 46100000 Gain TERT Pancreatic endocrine tumor
14 206334 6 139000000 149000000 Loss Endocrine pancreatic tumor
15 225336 7 45020224 55392724 Gain EGFR Pancreatic endocrine tumor
16 236915 8 18983547 53650298 Loss BNIP3L Pancreatic endocrine tumor

Expression for Pancreatic Neuroendocrine Tumor

Search GEO for disease gene expression data for Pancreatic Neuroendocrine Tumor.

Pathways for Pancreatic Neuroendocrine Tumor

GO Terms for Pancreatic Neuroendocrine Tumor

Biological processes related to Pancreatic Neuroendocrine Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cardiac muscle contraction GO:0060048 9.43 MTOR PIK3CA
2 positive regulation of nitric oxide biosynthetic process GO:0045429 9.4 CLU MTOR
3 positive regulation of neuron death GO:1901216 9.37 CLU MTOR
4 cell aging GO:0007569 9.32 BRCA2 MTOR
5 negative regulation of macroautophagy GO:0016242 9.26 MTOR PIK3CA
6 inner cell mass cell proliferation GO:0001833 9.16 BRCA2 PALB2
7 anoikis GO:0043276 8.96 MTOR PIK3CA
8 multicellular organism growth GO:0035264 8.8 BRCA2 MTOR PALB2

Sources for Pancreatic Neuroendocrine Tumor

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....